Artiva Biotherapeutics, a biotech company focused on developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers, has refiled for a $100 million IPO. This follows a previous attempt in 2021 and a withdrawal in 2022. The company aims to use the funds to advance its NK cell therapy programs, particularly after losing a partnership with Merck. Artiva's revised IPO pitch highlights its NK cell therapy for autoimmune diseases.
With revised IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease https://t.co/ByogZPMhdp by @BentheFidler
Having lost Merck partnership, Artiva looks to IPO to fund NK cell therapy https://t.co/EyjsC9IlQR #biotech #news
With revised #IPO pitch, Artiva touts ‘natural killer’ cell therapy for autoimmune disease https://t.co/LrsTTbRdH1 $ARTV $FATE $NKTX $KYTX $CABA
Biotech focused on developing natural killer (NK) cell-based therapies for patients suffering from devastating autoimmune diseases and cancers, Artiva Biotherapeutics Inc., filed for #IPO. $ARTV *Previously Withdrawn in 2022* https://t.co/RSe8NMc2u8
“Autoimmune biotech” $ARTV Would be fun to compare the new S-1 to the former https://t.co/IRYVxlOvcF
“Autoimmune biotech” $ARTV https://t.co/IRYVxlOvcF
Autoimmune biotech Artiva Biotherapeutics refiles for a $100 million IPO, following attempt in 2021 $ARTV $IPO #IPO https://t.co/qzC9m7ahV9